Patents by Inventor Harry Ralph Howard, Jr.

Harry Ralph Howard, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7101886
    Abstract: This invention relates to compounds of the formula 1 wherein R1, R3, R4, X1, and X2 are defined as in the specification, pharmaceutical compositions containing them and their use in the treatment of central nervous system and other disorders.
    Type: Grant
    Filed: November 7, 2003
    Date of Patent: September 5, 2006
    Assignee: Warner Lambert Company
    Inventors: Stephen Sung Yong Cho, Jamie Marie Singer, James M. Graham, Tracy Fay Gregory, Harry Ralph Howard, Jr., Sham Shridhar Nikam, Michael Anthony Walters
  • Patent number: 7084165
    Abstract: The present invention relates to compounds that are useful exhibit activity as serotonin, norepinephrine and dopamine reuptake inhibitors, and their pharmaceutically acceptable salts, and their use in the treatment of central nervous system and other disorders.
    Type: Grant
    Filed: September 4, 2003
    Date of Patent: August 1, 2006
    Assignee: Pfizer Inc
    Inventors: Harry Ralph Howard, Jr., Christopher Joseph Schmidt, Thomas Francis Seeger, Mark Leonard Elliot
  • Patent number: 6610747
    Abstract: A compound of general formula (I) wherein R1 and R2 are H, C1-C6alkyl or (CH2)d(C3-C6cycloalkyl) wherein d=0, 1, 2 or 3; or R1 and R2 together with the nitrogen to which they are attached form an azetidine ring; Z or Y is —SR3 and the other Z or Y is halogen or —R3; wherein R3 is C1-C4 alkyl optionally substituted with fluorine; except that R3 is not CF3; or Z and Y are linked so that, together with the interconnecting atoms, Z and Y form a fused 5 to 7-membered carbocyclic or heterocyclic ring, and wherein when Z and Y form a heterocyclic ring, in addition to carbon atoms, the linkage contains one or two heteroatoms independently selected from oxygen, sulfur and nitrogen; R4 and R5, which may be the same or different, are: A—X, wherein A=—CH═CH— or —(CH2)p— where p is 0, 1 or 2; X is hydrogen, F, Cl, Br, I, CONR6R7, SO2NR6R7, SO2NHC(═O)R6, OH, C1-4alkoxy, NR8SO2R9, NO2, NR6R11, CN, CO2R10, CHO, SR10, S(O)R9 or SO2R10; or a 5- or 6-membered het
    Type: Grant
    Filed: August 27, 2001
    Date of Patent: August 26, 2003
    Assignee: Pfizer Inc.
    Inventors: Mavis Diane Adam, Mark David Andrews, Mark Leonard Elliott, Geoffrey Edward Gymer, David Hepworth, Harry Ralph Howard, Jr., Donald Stuart Middleton, Alan Stobie
  • Patent number: 6436938
    Abstract: The present invention relates to a method of treating depression, especially refractory depression, in a mammal, including a human, by administering to the mammal a sigma receptor ligand in combination with an antidepressant agent. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a sigma receptor ligand and a serotonin reuptake inhibitor.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: August 20, 2002
    Assignee: Pfizer Inc.
    Inventor: Harry Ralph Howard, Jr.